PARIS, FRANCE: Inventiva, a clinical-stage biopharmaceutical company, has completed sales of 2.083 million American Depositary Shares (ADS) pursuant to the company’s ATM program established on August 2, 2021, through Jefferies LLC. Each American Depositary Shares (ADS) represents one ordinary share of the company.
In the ATM sales, an aggregate of 2,083,334 new American Depositary Shares (ADS) and the same number of underlying new ordinary shares have been issued to existing and new specialized institutional investors through a capital increase at a price of $14.40 per new ADS, without a discount to the volume weighted average price of the company’s ADS over the last trading day and representing a discount of 3% to the volume weighted average price of the company’s ordinary shares on the regulated market of Euronext in Paris over the last trading day.
The new shares will represent 5.1% of the share capital of the company upon completion of the transaction.
It is anticipated that the settlement and delivery of the new shares will take place on September 27, 2021. They will be admitted to trading on Euronext and the issued ADSs will trade on Nasdaq.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris and on the Nasdaq Global Market in the United States. www.inventivapharma.com